Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Paclitaxel, Estramustine, and Carboplatin in HRPC
NCT00193193Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Aug 2000
- Primary completion
- Dec 2003
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, randomised, open-label trial of paclitaxel, estramustine and carboplatin in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate. Started Aug 2000; status: completed.
02
Drugs
paclitaxelestramustinecarboplatin
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT00193193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193193.